Clinical Trials

 

Gates Institute supports the following trials of chimeric antigen receptor (CAR) T-cell therapy at CU Anschutz Medical Campus:

  • Opened 2020 at UCHealth: Phase 1 study of feasibility and safety of UCD19 CAR T cells in adult patients with relapsed and/or refractory B-cell non-Hodgkin lymphoma (B-NHL). 
  • Opened 2021 at Children’s Hospital Colorado: Phase 1/2 dose escalation and preliminary efficacy study of UCD19 CAR T cells in pediatric patients with relapsed and/or refractory B-cell acute lymphoblastic leukemia (B-ALL) and B-NHL.
  • Opened 2022 at UCHealth: Phase 1/1b study of bispecific CD19x22 CAR T cells in adolescent and adult patients with relapsed and/or refractory B-NHL.
  • Opened 2023 at UCHealth: Phase 1 safety and tolerability trial of CD19 CAR T cells in adult patients with B-cell acute lymphoblastic leukemia (B-ALL) with minimal residual disease positive at first complete remission; enrollment opened July 2023.